SynKinase
Tandutinib
As low as
CHF 71.00
In stock
Only %1 left
SYN-1088-M0011 mgCHF 71.00
SYN-1088-M0055 mgCHF 92.00
SYN-1088-M01010 mgCHF 106.00
SYN-1088-M05050 mgCHF 128.00
SYN-1088-M100100 mgCHF 170.00
Specifications / Handling
| Product Details | |
|---|---|
| Synonyms | CT53518; MLN518 |
| Product Type | Chemical |
| Properties | |
| Formula | C31H42N6O4 |
| MW | 562.7 |
| CAS | 387867-13-2 |
| Purity Chemicals | ≥95% |
| Appearance | Solid. |
| Solubility | Soluble in DMSO or ethanol. |
| Declaration | Manufactured by SynKinase. |
| Other Product Data |
Target: PDGFR | Kinase Group: RTK | Substrate: Tyrosine Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet. |
| InChi Key | UXXQOJXBIDBUAC-UHFFFAOYSA-N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| Safety Data Sheet |
Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Scientific Background Information
Product Description
Tandutinib inhibits the auto-phosphorylation of FLT3 (FMS-Like Tyrosine kinase-3, IC(50) of 0.22µM), c-KIT and PDGF (platelet-derived growth factor), thereby inhibiting cellular proliferation and inducing apoptosis.
Product-specific References
- CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML): L.M. Kelly, et al.; Cancer Cell 1, 421 (2002)
You're in the Switzerland store. Not in Switzerland? Choose your country
You're in the Switzerland store (prices in CHF, shipping to Switzerland only). Ordering from another country? Please select it below.
Please note that not all products are available in every country store. Choose your country before starting the ordering process.
Country
Switzerland
United Kingdom
France
Germany
Austria
Italy
South Korea
United States
Argentina
Australia
Belgium
Bosnia and Herzegovina
Brazil
Canada
Chile
China
Colombia
Cyprus
Czech Republic
Denmark
Ecuador
Egypt
Estonia
Finland
Greece
Hong Kong
Hungary
India
Iran
Iraq
Ireland
Israel
Japan
Latvia
Lithuania
Luxembourg
Malaysia
Mexico
Netherlands
New Zealand
Norway
Pakistan
Peru
Poland
Portugal
Romania
Russia
Singapore
Slovakia
Slovenia
South Africa
Spain
Sweden
Syria
Taiwan
Thailand
Turkey
Uruguay
Venezuela
Other Country
No country found




Download PDF